Goldman Sachs’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-293,489
| Closed | -$6.77M | – | 5531 |
|
|
2020
Q4 | $6.77M | Buy |
293,489
+237,045
| +420% | +$5.47M | ﹤0.01% | 2292 |
|
|
2020
Q3 | $575K | Buy |
56,444
+24,067
| +74% | +$245K | ﹤0.01% | 3602 |
|
|
2020
Q2 | $482K | Buy |
32,377
+11,712
| +57% | +$174K | ﹤0.01% | 3617 |
|
|
2020
Q1 | $252K | Buy |
20,665
+5,086
| +33% | +$62K | ﹤0.01% | 3850 |
|
|
2019
Q4 | $247K | Buy |
+15,579
| New | +$247K | ﹤0.01% | 3923 |
|
|
2019
Q3 | – | Sell |
-37,642
| Closed | -$497K | – | 4388 |
|
|
2019
Q2 | $497K | Buy |
+37,642
| New | +$497K | ﹤0.01% | 3531 |
|